| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 |
| filingDate |
1993-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1998-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_777e25020b11b713545dcbabdb3ee3c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08a6fa5dbbce734307159dea4154f90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60aa5999cca48c617f16925df2dde674
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd9592af641f2f7697acc16f198d0c65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b3830ddb77213fbc7987496931faf98 |
| publicationDate |
1998-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5837852-A |
| titleOfInvention |
Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease |
| abstract |
Novel capped oligonucleotides useful in treatment of influenza infection. A synthetically derived 67-nucleotide RNA substrate, containing a [32P] labeled cap-1 structure was used to analyze parameters of influenza virus endonuclease activity. This substrate was specifically cleaved by the influenza virus polymerase to yield a single capped 11-nucleotide fragment capable of directly priming transcription. An analysis of systematic truncations of this RNA substrate in cleavage, elongation, and binding reactions demonstrated that the minimum chain length required for cleavage was one nucleotide past the cleavage site. In contrast, the minimum chain length required for priming activity was found to be 9 nucleotides, while a chain length of at least 4 nucleotides was required for efficient binding. Based on these chain length requirements, the present inventors show that a pool of capped oligonucleotides-too short to prime transcription but long enough to bind with high affinity to the viral polymerase-are potent inhibitors of cap-dependent in vitro transcription. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7812149-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7695902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7884086-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8604183-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6369208-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011520464-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8569474-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011165226-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004044138-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9061041-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9408863-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9416154-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2123758-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8394947-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9096636-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9150603-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101970465-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101970465-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9156872-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009142494-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012165515-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8481712-B2 |
| priorityDate |
1993-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |